Learn more about Pfizer Inc.'s (PFE) stock grades for Value, Momentum, Growth and Estimate Revisions and determine whether ...

In my March article, "Why Pfizer Remains A Strong Buy In 2026", I mainly discussed Pfizer's Q4 earnings ( PFE) and the ...

The pharmaceutical powerhouse still faces plenty of patent challenges, but it got a big one out of the way, securing time and ...

Pfizer (NYSE:PFE | PFE Price Prediction) at $25.75, Molina Healthcare (NYSE:MOH) at $186.80, and Halliburton (NYSE:HAL) at ...

The healthcare giant has been investing heavily in its future growth.

Pfizer (NYSE: PFE) continues to lag the market. Over the past few years, the company has generally reported declining revenue and profits, resulting in a substantial decline in market value. The ...

Although the stock market may seem hot these days and largely overvalued, there are some gems you can find out there, with ...

Pfizer's growth rate has tanked in recent years, and investors remain concerned about the future. The company has been loading up on acquisitions to bolster its pipeline, but it could still be years ...

Pfizer and its partners have granted Rigel Pharmaceuticals an exclusive license to commercialize VEPPANU (vepdegestrant), the ...

Pfizer stock slipped after Q1 results despite an earnings beat as investors weighed falling COVID sales and looming patent expirations.

The next-generation version of Pfizer's $6 billion pneumococcal vaccine franchise topped its predecessor in a midstage study.